ZMYND8 and breast carcinoma: disclosed that ZMYND8 inhibits cytotoxic T cell-mediated anti-tumor immunity by suppressing the release of IFN-β from breast cancer cells, causing breast cancer cells to escape immune surveillance and promote tumorigenesis (38).